The Top Line
Claim This Podcastby Fierce Life Sciences
Podcast Authority
Beta
Podcast Overview
<p>Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. </p>
Language
🇺🇲
Publishing Since
5/3/2022
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
Podcast Authority
BetaRecommendations available
Unlock the full report to see detailed tips
Recommendations available
Unlock the full report to see detailed tips
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
See how your show performs across every key metric
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for The Top Line
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 10, 2026
A $10B deal, China trial scrutiny and highlights from ADA 2026
Fierce Pharma Senior Editor Fraiser Kansteiner and Fierce Pharma Marketing's Zoey Becker interview industry experts on Vertex's $10B acquisition, China trial scrutiny, and evolving obesity data at ADA 2026.
June 26, 2026
The deal before the deal
Senior Editor James Waldron interviews Kaleem Chowdhury, Ph.D., Liz Leveille, and Abbas Kazemi about the intricate realities of biopharma dealmaking and relationship building before agreements are finalized.
June 16, 2026
FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)
Host Stephanie Butler interviews Sheila Plant, vice president of regulatory affairs at Allucent, about strategically leveraging FDA Breakthrough Therapy and RMAT designations to accelerate oncology development.
253 total episodes available with 166 transcripts
Recent guests on The Top Line
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Fraiser Kansteiner
Guest
Zoey Becker
Guest
Kaleem Chowdhury
Guest
Liz Leveille
Guest
Abbas Kazemi
Guest
Sheila Plant
Guest
Christelle Huguet
Guest
Amer Zeidan
Guest
Uli Stilz
Guest
Bruce Beutel
Guest
Ben Bradford
Guest
Jeremy Richardson
Guest
Similar Podcasts
Discover related shows you might enjoy
BioCentury This Week
BioCentury
The Readout Loud
STAT
Biotech Hangout
Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
The Long Run with Luke Timmerman
Timmerman Report
WSJ Your Money Briefing
The Wall Street Journal
WSJ's Take On the Week
The Wall Street Journal
WSJ Tech News Briefing
The Wall Street Journal
ASCO Daily News
American Society of Clinical Oncology (ASCO)
The BioCentury Show
BioCentury
HBR IdeaCast
Harvard Business Review
a16z Podcast
Andreessen Horowitz
HBR On Leadership
Harvard Business Review
FT News Briefing
Financial Times
The McKinsey Podcast
McKinsey & Company
Bloomberg Businessweek
Bloomberg
Deep-dive analytics for The Top Line
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is The Top Line?
<p>Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. </p> - How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.